| Literature DB >> 27717920 |
Lauren Powell1, Jack Parker, Marrissa Martyn St-James, Susan Mawson.
Abstract
BACKGROUND: With advances in technology, the adoption of wearable devices has become a viable adjunct in poststroke rehabilitation. Regaining ambulation is a top priority for an increasing number of stroke survivors. However, despite an increase in research exploring these devices for lower limb rehabilitation, little is known of the effectiveness.Entities:
Keywords: gait; rehabilitation; stroke; wearable technology
Mesh:
Year: 2016 PMID: 27717920 PMCID: PMC5075044 DOI: 10.2196/jmir.5891
Source DB: PubMed Journal: J Med Internet Res ISSN: 1438-8871 Impact factor: 5.428
Inclusion and exclusion criteria for this review.
| Inclusion criteria | Exclusion criteria |
| English language articles | Studies including upper limb |
| Studies recruiting people over the age of 18 years | Studies where the intervention is not clearly defined |
| Studies evaluating lower-limb and wearable technology | Studies not using one of the chosen 11 outcome measures (see Outcome measurement/assessment below) |
| Studies reporting an RCTa | Studies not reporting an RCTa |
| Studies measuring activity and participation as classified by the World Health Organization ICFb | Studies not measuring activity and participation as classified by the World Health Organization ICFb |
aRCT: randomized controlled trial.
bICF: International Classification of Functioning, Disability and Health.
Figure 1Selection of articles for review.
Risk of bias summary.
| Random | Allocation | Blinding of | Blinding of | Incomplete | Selective | Overall | |
| Bauer, 2015 [ | Low risk | Low risk | High risk | Low risk | High risk | Low risk | High risk |
| Bradley, 1998 [ | Unclear | Unclear | Unclear | Unclear | High risk | Unclear | High risk |
| Dorsch, 2015 [ | Low risk | Unclear | Unclear | Low risk | High risk | Low risk | High risk |
| Intiso, 1994 [ | Unclear | Unclear | Unclear | Low risk | High risk | Unclear | High risk |
| Mansfield, 2015 [ | Low risk | Low risk | Unclear | Low risk | Low risk | Low risk | Low risk |
| Mirelman, 2009 [ | Unclear | Unclear | High risk | Unclear | Low risk | Unclear | Unclear |
| Salisbury, 2013 [ | Low risk | Low risk | Unclear | High risk | Low risk | Unclear | High risk |
| Shamay, 2009 [ | Low risk | Unclear | High risk | Low risk | High risk | Unclear | High risk |
| Solopova, 2011 [ | Unclear | Unclear | Unclear | Unclear | Low risk | Unclear | Unclear |
| Stein, 2014 | Unclear | Unclear | Unclear | Unclear | Low risk | Low risk | Unclear |
| Watanabe, 2014 [ | High risk | Unclear | High risk | High risk | High risk | Low risk | High risk |
Study, participant, and intervention characteristics and results.
| Authors, year, country, study design | Number recruited (N) & final follow-up (n) overall and between groups | Gender, mean age, L/Ra hemisphere stroke, mean time since stroke | Intervention length/ frequency | Activity and participation outcome measure(s) | Activity and participation outcome results summary and reported |
| Bauer et al, 2015 [ | N (n)=40 (21). 21 (12), intervention; 19 (9), control | 9M/9Fd, 64±11 years, 10R/8L, 42±45 days (control), 12M/7F, 59±14 years, 5R/14L, 62±43 days (intervention) | 20 mins, 3x/week over 4 weeks. Total of 12 sessions | FACe, 10MWTf | The intervention group increased by a median of 2 categories for the FAC and a median of 1 category for the control group ( |
| Bradley et al, 1998 [ | N (n)=23 (21); 12 (12) intervention, 11 (9) control | 12M/11F, 77/68 yrs (mild/severe control), 66.6/72.4yrs (mild/se- vere intervention), 5L/16R, 35.6 days | 6 weeks/ 3x/week | RMI, 10MWT, Nottingham ADL | No significant between-group differences (RMI, 10MWT, Notting- ham ADL), although all groups improved in time taken and step count for the 10MWT and all groups improved their Nottingham ADL scores |
| Dorsch et al, 2015 [ | N (n)=151 (125). 73 (58) SF; 78 (67) AF | 28%F/72%M | Feedback provided 3x/week, weekend use of accelerometers was optional | FAC | No significant between-group differences found for the FAC ( |
| Intiso et al, 1994 [ | N (n)=16 (14), 8 (8) intervention, 8 (6) control) | 9M,/7F, 53.5yrs (control), 61.3yrs (intervention), 9R/7L, 8.3 months (control), 11.3 months (intervention) | 2 months/60 mins daily | BIm | No significant between-group differences (BI), 4/8 participants found to have significant increased BI scores |
| Mansfield et al, 2015 [ | N (n)= 60 (57). 29 (29) intervention; 31 (28) control | 20M/9F, 64yrs, 11R/16L/2B, 26 days (intervention) 16M/12F, 61.5yrs, 13R/13L/2B, 23 days (control) | 3-26 days per participant in each group. Mode=11 days per participant | BBSn | No significant between-group differences step numbers ( |
| Mirelman et al, 2009 [ | N (n)=18 (18), 9 (9) intervention, 9 (9) control) | 15M/3F, 61yrs (control), 61.8yrs (intervention), 8R/10L, 58.2 months (control), 37.7 months (intervention) | 4 weeks/60 mins 3x/week | BBS, 6MWTp | No significant between-group differences (6MWT), BBS results/ |
| Salisbury et al, 2013 [ | N (n)=16 (14). 9 (8) intervention, 7 (6) control | 6M/10F, 52.6yrs (control), 55.8yrs (intervention), 10R/6L, 69days (control), 51.7 days (intervention) | 12 weeks/20 mins 5 days/ week | FAC, 10MWT (velocity & cadence), SIS | No significant between-group differences observed (FAC 6 weeks |
| Shamay, 2009 [ | N (n)=109 (101). 29 (27) control, 28 (25) TENS, 25 (23) placebo+Exr, 27 (26) TENS+Ex | 85M/24F, 56.5yrs, 57.8yrs (TENS+Ex), 56.9yrs (placebo stimulation+Ex), 55.5yrs (control), 10%R/18%L [ | 4 weeks/TENS: 60 mins electrical stimulation, TENS+Ex & placebo stimulation + Ex 60 mins of Ex then 60 mins electrical or placebo stimulation. Subjects attended 8 instruction sessions prior to data collection | 6MWT, TUGs | Compared to all other groups, TENS+Ex group showed significant decreased TUG results ( |
| Solopova et al, 2011 [ | N (n)=61 (61). 32 intervention, 29 control | 33M/28F, 64±18yrs, 19R/42L, 9.3±4.5 days (control), 8.2±4.3 days (intervention) | 2 weeks/30 mins 5 days per week | BI | No significant between-group differences, Significant improvements after the intervention in the experimental group were observed (BI |
| Stein et al, 2014 [ | N (n)=12 (10), 12 (10) intervention, 12 (10) control) | 58%M (control), 83%M (intervention), 57.6yrs (control), 56.6yrs (intervention), L/R stroke not reported, 88.5 months (control), 49.1 months (intervention) | 6 weeks/60 mins 3 days per week | BBS, 6MWT, TUG, 10MWT, EFAPt | BBS scores favored the intervention group and the EFAP scores favored the control group. No statistically significant between-group differences observed (BBS, 6MWT, TUG, 10MWT, EFAP) |
| Watanabe et al, 2014 [ | N (n)=32 (22). 17 (11) intervention, 15 (11) control | 11M/11F, 75.6±13.9 (control), 67.0±16.8 (intervention), 11R/11L, 50.6±33.8 days (control), 58.9±46.5 days (intervention) | 4 weeks/12 20-min sessions | 6MWT, FAC, TUG, SPPBv | No significant between-group differences were observed (6MWT, TUG, FAC, SPPB). Intervention group improved more than the control group (FAC |
aL/R/B: left/right/both hemisphere stroke.
bRCT: randomized controlled trial.
cFES: functional electrical stimulation.
dM/F: male/female.
eFAC: functional ambulatory category.
f10MWT: 10 Meter Walk Test.
gPOMA: Performance-Oriented Mobility Assessment.
hEMG: electromyography.
iRMI: Rivermead Mobility Index.
jADL: activities of daily living.
kAF: augmented feedback.
lSIS: Stroke Impact Scale.
mBI: Barthel Index.
nBBS: Berg Balance Scale.
oSEQ: Stroke Self-Efficacy Questionnaire.
p6MWT: 6 Minute Walk Test.
qTENS: transcutaneous electrical nerve stimulation.
rEx: exercise.
sTUG: Timed Up and Go Test.
tEFAP: Emory Functional Ambulation Profile.
uHAL: Hybrid Assistive Limb.
vSPPB: Short Physical Performance Battery.